These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 6111611)

  • 1. Inhibition of neurotransmitter receptor binding by ergot derivatives.
    Hruska RE; Silbergeld EK
    J Neurosci Res; 1981; 6(1):1-11. PubMed ID: 6111611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central monoamine synapses as sites of action for ergot drugs.
    Fuxe K; Ogren SO; Agnati LF; Andersson K; Hall H; Köhler C; Fredholm B
    Adv Biochem Psychopharmacol; 1980; 23():41-62. PubMed ID: 6104914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoaminergic involvement in the behavioral effects of ergot derivatives.
    Appel JB; Cunningham KA; West KB
    Prog Clin Biol Res; 1985; 192():51-62. PubMed ID: 2867556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of the behavioral effects of lysergic acid diethylamide, 2,5-dimethoxy-4-methylamphetamine, quipazine and lisuride by 5-hydroxytryptamine antagonists.
    Mokler DJ; Commissaris RL; Warner MR; Rech RH
    J Pharmacol Exp Ther; 1983 Dec; 227(3):557-62. PubMed ID: 6655557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic and serotonergic mediation of the discriminable effects of ergot alkaloids.
    Holohean AM; White FJ; Appel JB
    Eur J Pharmacol; 1982 Jul; 81(4):595-602. PubMed ID: 7117388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple serotonin receptors and their physiological significance.
    Peroutka SJ; Snyder SH
    Fed Proc; 1983 Feb; 42(2):213-7. PubMed ID: 6337063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interaction of lisuride, an ergot derivative, with serotonergic and dopaminergic receptors in rabbit brain.
    Rosenfeld MR; Makman MH
    J Pharmacol Exp Ther; 1981 Mar; 216(3):526-31. PubMed ID: 7205633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropharmacology of synthetic ergot derivatives in man.
    Lemberger L; Crabtree RE
    Adv Biochem Psychopharmacol; 1980; 23():117-24. PubMed ID: 6104905
    [No Abstract]   [Full Text] [Related]  

  • 9. Serotoninergic receptors in brain tissue: properties and identification of various 3H-ligand binding sites in vitro.
    Leysen JE
    J Physiol (Paris); 1981; 77(2-3):351-62. PubMed ID: 7288650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions of ergot alkaloids with anterior pituitary D-2 dopamine receptors.
    Sibley DR; Creese I
    Mol Pharmacol; 1983 May; 23(3):585-93. PubMed ID: 6223205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selectivity of some ergot derivatives for 5-HT1 and 5-HT2 receptors of rat cerebral cortex.
    Beart PM; McDonald D; Cincotta M; de Vries DJ; Gundlach AL
    Gen Pharmacol; 1986; 17(1):57-62. PubMed ID: 3949149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Displacement of specific serotonin and lysergic acid diethylamide binding by Ergalgin, a new antiserotonin drug.
    Oelszner W
    Acta Biol Med Ger; 1980; 39(8-9):897-901. PubMed ID: 7282219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The interactions of bromocriptine and lergotrile with dopamine and alpha-adrenergic receptors.
    Lew JY; Hata F; Ohashi T; Goldstein M
    J Neural Transm; 1977; 41(2-3):109-21. PubMed ID: 21229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in the dopaminergic effects of the ergot derivatives bromocriptine, lisuride and d-LSD as compared with apomorphine.
    Horowski R
    Eur J Pharmacol; 1978 Sep; 51(2):157-66. PubMed ID: 699981
    [No Abstract]   [Full Text] [Related]  

  • 15. Anorectic effect of lisuride and other ergot derivatives in the rat.
    Carruba MO; Ricciardi S; Müller EE; Mantegazza P
    Eur J Pharmacol; 1980 Jun; 64(2-3):133-41. PubMed ID: 6105081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of catecholamine-derived alkaloids with central neurotransmitter receptors.
    Nimit Y; Schulze I; Cashaw JL; Ruchirawat S; Davis VE
    J Neurosci Res; 1983; 10(2):175-89. PubMed ID: 6313954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective influence of ergot alkaloids on cortical and striatal dopaminergic and sergotonergic receptors.
    Rosenfeld MR; Makman MH; Ahn HS; Thal LJ; Mishra RK; Katzman R
    Adv Biochem Psychopharmacol; 1980; 23():83-93. PubMed ID: 6249092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discriminative stimulus properties of lergotrile.
    Cunningham KA; Callahan PM; Appel JB
    J Pharmacol Exp Ther; 1984 Jul; 230(1):47-52. PubMed ID: 6146709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro selectivity of lisuride and other ergot derivatives for alpha 1- and alpha 2-adrenoceptors.
    McPherson GA
    Eur J Pharmacol; 1984 Jan; 97(1-2):151-5. PubMed ID: 6321208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus.
    Almaula N; Ebersole BJ; Ballesteros JA; Weinstein H; Sealfon SC
    Mol Pharmacol; 1996 Jul; 50(1):34-42. PubMed ID: 8700116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.